BioMarin Pharmaceutical Inc.
BMRN
$67.48
-$0.84-1.23%
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 0.21% | 4.73% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 0.21% | 4.73% | |||
| Cost of Revenue | -27.76% | -40.03% | |||
| Gross Profit | 9.67% | 40.10% | |||
| SG&A Expenses | -32.63% | -3.63% | |||
| Depreciation & Amortization | 92.67% | -64.97% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -22.44% | 6.81% | |||
| Operating Income | 125.86% | -5.45% | |||
| Income Before Tax | 26.18% | 1.74% | |||
| Income Tax Expenses | 57.60% | 13.62% | |||
| Earnings from Continuing Operations | 17.78% | -1.02% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 17.78% | -1.02% | |||
| EBIT | 125.86% | -5.45% | |||
| EBITDA | 111.32% | -9.54% | |||
| EPS Basic | 17.61% | -1.17% | |||
| Normalized Basic EPS | 97.21% | 1.57% | |||
| EPS Diluted | 17.81% | -0.16% | |||
| Normalized Diluted EPS | 98.03% | 3.47% | |||
| Average Basic Shares Outstanding | 0.14% | 0.17% | |||
| Average Diluted Shares Outstanding | -0.29% | -1.67% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
